Updated WHO policy recommendation: Single dose primaquine as a gametocytocide in Plasmodium falciparum malaria

October 2012

World Health Organization

Publication details

Number of pages: 1
Publication date: 2012
Languages: English



Primaquine potentially has a major role in reducing malaria transmission, especially in efforts to eliminate Plasmodium falciparum malaria. The population benefits of reducing malaria transmission by gametocytocidal drugs require that a very high proportion of patients receive these medicines.

Based on the review of the WHO Evidence Review Group, the Malaria Policy Advisory Committee (MPAC) recommends the following:

  • In: (1) areas threatened by artemisinin resistance where single dose primaquine as a gametocytocide for P. falciparum malaria is not being implemented, and (2) elimination areas which have not yet adopted primaquine as a gametocytocide for P. falciparum malaria:

  • A single 0.25 mg base/kg primaquine dose should be given to all patients with parasitologically-confirmed P. falciparum malaria on the first day of treatment in addition to an ACT, except for pregnant women and infants <1 year of age.

Relevant considerations for the programmatic implementation of these recommendations are provided in the complementary policy brief.

Related documents